• Alias: E7080
    • A multitargeted tyrosine kinase inhibitor of VEGF receptors VEGFR1 (FLT1), VEGFR2 (KDR), VEGFR3 (FLT4), fibroblast growth factor receptors FGFR1, 2, 3, and 4, PDGFRα, KIT, and RET
    • FDA approved for differentiated thyroid carcinoma and advanced renal cell carcinoma
    • Recommended dose: 18 mg once daily (in combination with everolimus in the renal cell) or 24 mg daily (thyroid cancer)
    • Half-life: â™28 hours
    • Metabolism: Major CYP3A4 substrate
    • Common side effects: Hypertension, proteinuria, nausea/vomiting, diarrhea, stomatitis, anorexia, fatigue, QT prolongation, peripheral edema, arthralgia, cough
    Other topics in Targeted and Immunotherapy Agents